Daratumumab (Darzalex®). HTA ID: 22039

Assessment Status Full HTA submission received from Applicant
HTA ID 22039
Drug Daratumumab
Brand Darzalex®
Indication In combination with lenalidomide (Revlimid®) and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
Assessment Process
Rapid review commissioned 30/05/2022
Rapid review completed 30/06/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of daratumumab in combination with lenalidomide and dexamethasone for this indication compared with the current standard of care
Full pharmacoeconomic assessment commissioned by HSE 27/07/2022
Pre-submission consultation with Applicant 11/10/2022
Full submission received from Applicant 09/01/2023